Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03570892
Title Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

B-cell lymphoma

Therapies

Lenalidomide

Ibrutinib

Carboplatin + Etoposide + Ifosfamide + Rituximab

Carmustine + Cytarabine + Etoposide + Melphalan

Cisplatin + Dexamethasone + Gemcitabine + Rituximab

Cyclophosphamide + Fludarabine + Tisagenlecleucel

Cisplatin + Cytarabine + Dexamethasone + Rituximab

Gemcitabine + Oxaliplatin + Rituximab

Bendamustine + Fludarabine + Tisagenlecleucel

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST